Moberg Pharma AB (publ) represents values of innovation, growth, and patient-centered care. With a strong corporate philosophy focused on developing and commercializing innovative pharmaceutical solutions, Moberg Pharma aims to improve the lives of patients worldwide. The company's core values drive their commitment to excellence, integrity, and sustainability. Moberg Pharma AB (publ) is dedicated to delivering high-quality products and driving long-term growth through strategic partnerships and expansion into new markets. By prioritizing patient needs and embracing innovation, Moberg Pharma aims to make a positive impact on global healthcare.

Moberg Pharma AB (publ) primarily operates in the United States, Sweden, and other key markets worldwide. With a global presence, the company focuses on offering innovative products across different regions to cater to the specific needs of consumers. The United States represents a significant market for Moberg Pharma AB (publ), where they have a strong presence and actively engage in expanding their market share. In Sweden, the company benefits from its home country advantage, leveraging its established presence and reputation. Additionally, Moberg Pharma AB (publ) extends its reach to other regions to maximize its international footprint and capture new growth opportunities.

Moberg Pharma AB (publ) has achieved several significant milestones. Firstly, they have successfully developed and commercialized numerous innovative pharmaceutical products in the dermatology field. Secondly, they have established strategic partnerships with major pharmaceutical companies, enhancing their market presence and distribution capabilities. Additionally, the company has expanded its product portfolio through acquisitions and successful licensing agreements. Moberg Pharma AB (publ) has also demonstrated strong financial performance, including revenue growth and profitability. Overall, their achievements showcase their dedication to advancing dermatology treatments and their commitment to delivering value to shareholders and stakeholders alike.

Moberg Pharma AB (publ) is a pharmaceutical company founded in 2006. Headquartered in Stockholm, Sweden, the company focuses on developing and commercializing innovative treatments for skin diseases and disorders. Moberg Pharma AB (publ) is known for its extensive portfolio of over-the-counter products and prescription medicines. The company has a strong track record of successfully launching and marketing its products globally. With a commitment to research and development, Moberg Pharma AB (publ) continues to collaborate with healthcare professionals to improve the lives of patients suffering from various dermatological conditions. With a dedicated team and a forward-thinking approach, Moberg Pharma AB (publ) is poised to remain a leader in the pharmaceutical industry.

The main competitors of Moberg Pharma AB (publ) in the market include companies like Johnson & Johnson, Pfizer Inc., GlaxoSmithKline, and Novartis AG. These companies operate in the pharmaceutical and healthcare industry, offering products and solutions that may compete with Moberg Pharma's portfolio. It is important for Moberg Pharma to stay innovative and differentiate itself from the competition in order to maintain its market position and attract investors.

Moberg Pharma AB (publ) is primarily active in the pharmaceutical industry.

Moberg Pharma AB (publ) operates with a business model focused on the development, marketing, and sales of innovative pharmaceutical products. The company specializes in finding solutions for various dermatological and podiatric conditions, offering both over-the-counter (OTC) and prescription treatments. Moberg Pharma AB (publ) aims to improve the quality of life for individuals suffering from conditions such as nail fungus, haemorrhoids, and skin irritations. By conducting extensive research and development activities, collaborating with partners, and targeting global markets, Moberg Pharma AB (publ) strives to provide effective and accessible treatments to a wide range of consumers.

Moberg Pharma AB (publ) KGV ir -20,64.

Moberg Pharma AB (publ) KUV ir 53,55.

AlleAktien kvalitātes vērtējums Moberg Pharma AB (publ) ir 1/10.

gaidāmā Moberg Pharma AB (publ) apgrozījums ir 9,09 milj. SEK.

gaidāmā Moberg Pharma AB (publ) peļņa ir -23,58 milj. SEK.

Moberg Pharma AB (publ) is a publicly traded pharmaceutical company based in Sweden that focuses on the development, marketing, and sales of innovative over-the-counter products for the global market. The company is divided into three business areas: Consumer Health, Rx/Prescription, and Healthy Feet. The Consumer Health division is the largest and focuses on the development and marketing of OTC products for the self-medication market, including K4B and Emtrix. The Rx/Prescription division specializes in the development and marketing of prescription medications, such as MOB-015. The Healthy Feet division focuses on developing and marketing foot care and orthopedic products. Moberg Pharma prioritizes research and development and has partnerships with leading researchers and research institutions worldwide. The company operates in over 40 countries and has strong distribution and marketing structures in Europe and North America. Moberg Pharma aims to continually innovate and develop improved treatment options for patients worldwide.

Moberg Pharma AB (publ) izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Moberg Pharma AB (publ) vai uzņēmums nedod dividendes.

Moberg Pharma AB (publ) ISIN ir SE0013121340.

Moberg Pharma AB (publ) WKN ir A2PUSM.

Moberg Pharma AB (publ) simbols ir MOB.ST.

Pēdējo 12 mēnešu laikā Moberg Pharma AB (publ) maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Moberg Pharma AB (publ) plāno maksāt dividendes 0 SEK apmērā.

Moberg Pharma AB (publ) pašreizējā dividendu rentabilitāte ir .

Moberg Pharma AB (publ) maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Moberg Pharma AB (publ) pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 SEK. Tas atbilst dividendes ražībai 0 %.

Moberg Pharma AB (publ) tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Moberg Pharma AB (publ) apmērā 0 SEK, kas tika izmaksāta 24.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 24.10.2024..

Pēdējās dividendes izmaksa notika 24.10.2024..

Gadā 2023, Moberg Pharma AB (publ) izmaksāja 0 SEK dividendes.

Moberg Pharma AB (publ) dividendes tiek izmaksātas SEK.